Skip to Content

Research & Funding

Past Other NCI & NIH InitiativesRSS

This page lists past other NCI and NIH cancer imaging initiatives, including grant mechanisms.

Requests for Application (RFA) are usually announced with special application dates; there is no possibility for applying after that date. Program Announcements (PA, PAR) may be open for a set period of time, such as 3 years or less; applications submitted in response to Program Announcements may be due on the standard dates (February 1, June1, and October 1) or may have special dates for receipt of applications. Please pay attention to these dates. Contact a CIP staff member if you have questions.

  • Biology of Breast Pre-Malignancies (R01) (NCI) (RFA-CA-07-047)

    • Release Date: July 09, 2007
    • Application Receipt Date: November 14, 2007
    • Expiration Date: November 15, 2007
    • Contacts:

      Anne Tatum, NCI, Phone: (301) 594-5371; E-mail:

    The purpose of this initiative is to stimulate multidisciplinary efforts focused on the characterization of the genetic, molecular, and/or cellular changes, and/or functional biology of pre-malignancy states of human breast cancer. The NCI solicits applications for research projects intended to facilitate the identification of those attributes of the earliest identifiable breast lesions that distinguish benign lesions from precancerous lesions. Applicants are encouraged to exploit resources and technologies that already exist, including imaging and nanotechologies. Projects taking advantage of information already available from well-validated animal model systems and quantitative modeling may also be appropriate. Two to three awards will be made.


  • High-end Instrumentation Grant Program (S10) (NCRR) (PAR-07-383)

    • Release Date: June 13, 2007
    • Application Receipt Date: September 17, 2007
    • Expiration Date: September 18, 2007
    • Contacts:

      Marjorie A. Tingle, Ph.D., NCRR, Phone: 301-435-0772; E-mail:

    The NCRR High-End Instrumentation Grant (HEI) program solicits applications from groups of NIH-supported investigators to purchase a single major item of equipment to be used for biomedical research that costs at least $750,000. The maximum award is $2,000,000. Instruments in this category include, but are not limited to, structural and functional imaging systems, macromolecular NMR spectrometers, high-resolution mass spectrometers, cryoelectron microscopes and supercomputers.



    • Release Date: May 29, 2007
    • Application Receipt Date: See below
    • Expiration Date: January 25, 2009
    • Contacts:

      Contact: Peter Lyster, Ph.D., NIGMS, Phone: 301-451-6446, Email:

    • Application Receipt Dates: May 24, 2007; September 24, 2007; January 24, 2008; May 24, 2008; September 24, 2008, January 24, 2009

    The NIH is interested in promoting research and developments in computational science and technology that will support rapid progress in areas of scientific opportunity in biomedical research. The Institutes and Centers of the NIH offer support through the current solicitation for fundamental research in biomedical information science and technology as well as for the development of new informatics, computational and mathematical tools and technologies.

    See full description in NIH Guide: PAR-07-344


    • Release Date: May 22, 2007
    • Application Receipt Date: See below
    • Expiration Date: See below
    • Contacts:

      Contact: Anthony Hayward, Ph.D., NCRR, Phone: 301-435-0790, Email:

    • Letters of Intent Receipt Date: September 24, 2007 (Extended to October 9, 2007 per NOT-RM-07-013)
    • Application Receipt Date: October 24, 2007 (Extended to November 7, 2007 per NOT-RM-07-013)
    • Expiration Date: October 25, 2007 (Extended to November 8, 2007 per NOT-RM-07-013)

    The goal of the Institutional Clinical and Translational Science Award (CTSA) program is to transform the local, regional and national environment for clinical and translational science, thereby increasing the efficiency and speed of clinical and translational research. This transformation will be achieved by creating an academic home, which can be a center, department, or Institute (C/D/I), comprising faculty and programs that integrate clinical and translational science across multiple departments, schools, clinical and research institutes and hospitals. The C/D/I should provide clinical research resources including infrastructure and training to various disciplines in its institution (e.g., medicine, dentistry, nursing, pharmacy, public health, biostatistics, epidemiology, bioengineering) for the benefit of researchers, trainees, and research projects across multiple aspects of health promotion and disease prevention, pre-emption, and treatment studied by a wide range of NIH Institutes and Centers.

    See full description in NIH Guide: RFA-RM-07-007

  • PAR-07-235: Continued Development and Maintenance of Software (R01) (Multiple ICs)

    • Release Date: February 23, 2007
    • Application Receipt Date: May 17, 2007 and September 13, 2007
    • Expiration Date: September 14, 2007
    • Contacts:

      Jennifer A Couch, Ph.D., NCI, Phone: 301-435-5226, Email:

    • Peer Review Date(s): October, 2007 and February, 2008

    Biomedical research laboratories increasingly undertake a software development project to solve a problem of interest to that laboratory. These software packages sometimes become useful to a much broader community of users that can include translational and clinical researchers. The goal of this program announcement is to support the continued development, maintenance, testing and evaluation of existing software. The proposed work should apply best practices and proven methods for software design, construction, and implementation to extend the applicability of existing biomedical informatics/computational biology software to a broader biomedical research community.


  • Nanoscience and Nanotechnology in Biology and Medicine (R01: PAR-07-270); (R21: PAR-07-271)

    This funding opportunity (FOA) is aimed at enhancing nanoscience and nanotechnology research focused on problems in biology and medicine. Nanoscience and nanotechnology refer to research and development on the understanding and control of matter at a length scale of approximately 1 - 100 nanometers, where novel properties and functions occur because of the size. The National Cancer Institute (NCI) is interested in: 1. Early detection of the disease using imaging, 2. In vitro early diagnostics: multiplexed sensitive and specific sensors, 3. Multi-functional therapeutics and localized therapy delivery, and 4. Tools and approaches to interrogate, understand, and manipulate single cells, structures , and molecules.

    URL: (R01) (R21)

  • Etiology, Prevention, and Treatment of Hepatocellular Carcinoma (R01) (NIDDK, NIBIB, NIAAA) (PA-07-258)

    • Release Date: December 21, 2006
    • Application Receipt Date: Standard dates apply
    • Expiration Date: Expiration Date: September 2, 2008
    • Contacts:

      Contact: John Cole, Ph.D., NCI, Phone: 301-496-1718, Email:

    Research activities are encouraged in the broad areas of etiology and etiologic mechanism(s) of liver cancer, including: Identification of viral and host factors; development of animal models and in vitro viral cultivation methods; development of prevention and control strategies, including chemoprevention, validation of markers, and clinical trials of promising agents; and conduct of treatment and diagnosis research, including imaging studies.


  • PA-07-260 & PA-06-281: Understanding the effects of emerging cellular, molecular, and genomic technologies on cancer health care delivery (R01) & (R21) (NCI)

    • Release Date: December 21, 2006
    • Application Receipt Date: Standard dates apply
    • Expiration Date: January 3, 2009
    • Contacts:

      Louise Wideroff, Ph.D., NCI, Phone: 301-435-6823, Email:

    The purpose is to invite applications for health services research addressing utilization of cellular, molecular, and genetic or genomic (CMG) technologies in cancer care. The studies will assess CMG technologies in relation to: quality of care; organizational barriers and change factors in utilization; cost and cost-effectiveness; disparities in access and efficacy; monitoring of cross-sectional patterns of care and time trends; impact on existing standards of care, and; influence on cancer outcomes such as incidence, progression, mortality, survival, and quality of life. This funding opportunity specifically encourages research on commercially available CMG clinical tools already in use, as well as experimental tools in the later stages of development and/or in the regulatory approval pipeline.

    See full description in NIH Guide: R01 PA-07-260; R21 PA-06-281

  • Pathogenesis And Treatment Of Lymphedema And Lymphatic Diseases (R01) (PA-07-165)

    • Release Date: December 14, 2006
    • Application Receipt Date: Multiple dates, see announcement
    • Expiration Date: December 31, 2009, unless reissued
    • Contacts:

      Suresh Mohla, Ph.D., NCI, Phone: 301-435-1878, Email:

    The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research on the lymphatic system, to characterize its function on the molecular, cellular, tissue, organ, and intact organism levels and pathophysiologic mechanisms that cause disease, to develop new methods for imaging and/or quantitating lymph flow, and to discover new therapeutic interventions, including nursing, complementary and alternative treatments.


  • Ancillary Studies to the AD Neuroimaging Initiative (R01) (NIA, NIBIB) (PA-07-134)

    • Release Date: December 13, 2006
    • Application Receipt Date: Standard dates apply
    • Expiration Date: November 6, 2007
    • Contacts:

      Suresh Mohla, Ph.D., NCI, Phone: 301-435-1878, Email:

    This FOA invites research grant applications for ancillary studies to the Alzheimer's Disease Neuroimaging Initiative (ADNI), a multi-site, longitudinal, prospective, naturalistic study of normal cognitive aging, mild cognitive impairment (MCI), and early Alzheimer's disease (AD). The ADNI is collecting, processing, and storing serial blood, CSF, and urine samples in the three groups for analyses for potential biomarkers of disease progression, including genomic, proteomic, and metabolomic markers that can be correlated with clinical, neuropsychological, and imaging data.